Vanguard Therapeutics, Inc.

Organization Address
108 Eagle Trace Drive
Half Moon Bay, CA 94019-2286

Organization Phone
(415) 203-0436


Organization Description
Vanguard Therapeutics, Inc. is an early stage California company that is developing a disease changing, orally absorbable, cell adhesion-blocking drug for prophylactic therapy of sickle cell disease (SCD). Stephen Embury, M.D. our founder, is a physician-scientist, emeritus professor, and serial entrepreneur whose entire career has focused on SCD. Our program targets the abnormal blood flow that drives SCD and the adhesion of sickle red blood cells to the vascular endothelium that is fundamental to the abnormal blood flow. P-selectin on vascular endothelial cells is central to sickle red blood cell adhesion, and our parent compound effectively blocks P-selectin. With support of two phase-I SBIR grants from the NIH we have derived a superior component of that compound for use as our active drug substance in commercial development and developed a reliable ELISA for that drug substance. We currently are operating with a minimum number of active employees and a group of advisors/consultants who are leaders in the legal, scientific, pharmaceutical, and SCD fields. We are poised to pursue the IND-enabling formulation and testing activities needed for initiating human trials in one year.

Clinical Development Stage